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Abstract
Objectives: There has been a dramatic increase in the use of complementary medicines over recent decades. Glucosamine
is one of the most commonly used complementary medicines in Western societies. An understanding of glucosamine
consumption is of significance for public health and future health promotion. This paper, drawing upon the largest dataset
to date with regards to glucosamine use (n = 266,844), examines the use and users of glucosamine amongst a sample of
older Australians.
Design: Analysis of the self-reported data on use of glucosamine, demographics and health status as extracted from the
dataset of the 45 and Up Study, which is the largest study of healthy ageing ever undertaken in the Southern Hemisphere
involving over 265,000 participants aged 45 and over.
Results: Analysis reveals that 58,630 (22.0%) participants reported using glucosamine in the 4 weeks prior to the survey. Use
was higher for those who were female, non-smokers, residing in inner/outer regional areas, with higher income and private
health insurance. Of all the health conditions examined only osteoarthritis was positively associated with use of
glucosamine, while cancer, heart attack or angina and other heart disease were all negatively associated with glucosamine
use.
Conclusions: This study suggests that a considerable proportion of the Australia population aged 45 and over consume
glucosamine. There is a need for health care practitioners to enquire with their patients about their use of glucosamine and
for further attention to be directed to providing good quality information for patients and providers with regards to
glucosamine products.
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Introduction
The use of dietary supplements and complementary and
alternative medicine (CAM) has grown rapidly over the past few
decades [1,2] – a growth which has been associated with lifestyle
changes, population ageing, as well as the increasing prevalence of
chronic diseases (often proving difficult for conventional medicine
to address) [3–5].
Glucosamine is one of the most commonly used CAM with
recent research identifying 20% of the US adult population using
glucosamine [6]. In Australia, glucosamine is the most commonly
recommended CAM by GPs and community pharmacists, with
85.2% of GPs and 94.7% of Australian community pharmacists
recommending glucosamine to patients [7,8]. Three recent studies
on the use of conventional and complementary medicines among
Australians reported a glucosamine use of 15% (respondents aged
over 50) [9], 33% (respondents aged 60 or over) [10], and 24% (an
average respondent age of 66) [11].
Glucosamine is commonly used as a preventive measure and
treatment for joint problems and osteoarthritis [12,13]. For
example, a US study of 612 patients with osteoarthritis,
rheumatoid arthritis, or fibromyalgia found that glucosamine
was the most commonly used CAM (27% of patients reporting use)
[14]. Yet the evidence base for the effectiveness of glucosamine as
a treatment for osteoarthritis remains inconclusive and controver-
sial [15]. Meta-analyses of the effectiveness of glucosamine in
preventing or ameliorating the symptoms of osteoarthritis have
produced mixed findings [16–21]. Moreover, it has been suggested
that this heterogeneity of results could be exacerbated by factors
such as varying formulations (i.e. glucosamine sulfate vs. hydro-
chloride), variations in quality, industry bias, and/or methodolog-
ical variability [22,23].
Despite the extensive use of glucosamine, the topic has received
little attention to date. While previous broad CAM-focused studies
have provided prevalence rates for glucosamine use [6], there has
been little focused examination of the profile of glucosamine users
and the various factors influencing use. To date, only one study
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has examined the prevalence and factors associated with
glucosamine use among a general population [24] showing
glucosamine use among a random sample of 7,652 Canadians
over a 5-year period (1996–7 to 2001–2) increased substantially,
from 0.9% to 4.7% for men and from 1.3% to 8.2% for women.
This Canadian study found glucosamine use was higher among
women and increased with age and suggested glucosamine may be
used for the management of arthritis symptoms and/or as
a preventive health care measure. Glucosamine use was also
found to be associated with geographical region (higher use in
western Canada), arthritis, back/neck pain, higher calcium intake,
and regular physical activity [24].
The adverse effects of glucosamine have been well studied and
are considered uncommon and minor [25–27]. Nevertheless, there
are reports suggesting an interaction between glucosamine and
warfarin [28,29]2 a concern given the common usage of warfarin
(the most widely used oral anticoagulant in Australia) [30] and the
high rates of patient non-disclosure of CAM use to conventional
practitioners [31].
Given the rise of population ageing [32], increasing consumer
interest in the value of healthy eating, exercise and dietary
supplements [3], and growth in public awareness of the
importance of preventive health [33], an empirical analysis of
the prevalence and pattern of glucosamine consumption is of
significance for public health, future health promotion and the
regulation of consumer CAM products.
An understanding of the prevalence and pattern of glucosamine
use is crucial for an assessment of its benefits as well as the risk of
potential interactions with drugs such as warfarin in the general
population [34]. In response, this paper reports the findings of
a comprehensive study that examines the use and users of
glucosamine amongst a large sample of Australians (n = 266,848)
aged 45 years and older.
Method
Sample
This research utilised data collected through the 45 and Up
Study, which is the largest study of healthy ageing conducted in
the Southern Hemisphere and analyses data from over 266,000
men and women aged 45 and older who reside in the State of New
South Wales, Australia. The study is described in detail elsewhere
[35], but briefly participants for this study were randomly selected
from the Medicare Australia database, which provides virtually
complete coverage of the general population. Participants entered
the study by completing a baseline postal questionnaire and
providing written consent to have their health followed over time.
The 45 and Up study has the approval of the University of New
South Wales Ethics Committee and informed written consent of
the study participants was obtained. Participants joined the study
by completing a postal questionnaire. Recruitment began in
February 2006 and these analyses relate to the 266,848
participants joining the study to the end of December, 2009.
The overall response rate to the baseline questionnaire is estimated
to be 17.9%. The 45 and Up study sample has excellent
heterogeneity and is reasonably representative of the (State of)
New South Wales population; has a response rate comparable to
similar studies internationally and in Australia; and is among the
most representative large scale cohort studies in the world [36].
Use of Glucosamine
Participants were defined as being a glucosamine user if they
answered ‘yes’ to the following question: ‘In the past 4 weeks have
you taken glucosamine.’
Demographic Measures
Area of residence was assigned according to the Accessibility
Remoteness Index of Australia Plus [37] score for each
participant’s postcode. Participants were asked about their current
marital status, highest educational qualification they had complet-
ed, annual household income, and their level of healthcare
insurance.
Health Status Measures
Participants were asked to rate their overall health and overall
quality of life on a five-point Likert scale. They were also asked
about their history of smoking and amount of alcohol consump-
tion. Participants were provided with a list of diseases (e.g.
osteoarthritis, osteoporosis, asthma, cancer) and asked if they had
been treated for any of these diseases in the last month. Answers to
this question were used to determine whether a participant had
a particular disease or not.
Statistical Analyses
The demographic and health status characteristics of glucos-
amine users and non-users were compared using chi-square tests.
Logistic regression modelling, that included all demographic and
health status characteristics variables, was conducted using
a backward stepwise method, to parsimoniously predict use of
glucosamine. The model building process utilised the likelihood
ratio test to compare competing models. In response to the large
sample size and multiple comparisons, a p-value ,0.005 was
adopted for statistical significance. All analyses were conducted
using the statistical software program SAS, version 9.2 (SAS
Institute, Inc., Cary, NC, 2008).
Results
There were 266,844 participants who answered the question
regarding consumption of glucosamine, of which 58,630 (22.0%)
indicated that they had taken glucosamine in the 4 weeks prior to
the survey.
A comparison between participants who used glucosamine and
those who did not use glucosamine by demographic characteristics
is provided in Table 1. Use of glucosamine is highest among
females and those aged 60–79 years. Use of glucosamine was
higher for those participants: residing in inner regional areas;
having a trade, certificate or diploma education; having an annual
household income of $20000–$69999; being widowed, divorced or
separated; and having private health insurance (p,0.0001 for all
variables).
Table 2 shows a comparison between participants who used
glucosamine and those who did not use glucosamine by health
status characteristics. Use of glucosamine was highest among those
participants who never smoked, drank 7–13 alcoholic drinks per
week, whose overall health and quality of life were rated as being
very good, and who reported being treated for osteoarthritis,
osteoporosis, asthma, high blood pressure, high cholesterol, and
thyroid problems in the previous months. Conversely, participants
who reported being treated for cancer, heart attack or angina, and
other heart disease in the previous month were all lower users of
glucosamine (p,0.0001 for all but ‘other heart disease’,
p = 0.0004).
Table 3 shows the results of the multiple logistic regression
modelling. The odds of glucosamine use was 3.31 (95% CI: 3.18,
3.45) times greater for those participants reporting treatment for
osteoarthritis compared to those not reporting osteoarthritis. The
odds of glucosamine use was 0.85 (95% CI: 0.79, 0.91), 0.79 (95%
CI: 0.73, 0.86) and 0.82 (95% CI: 0.76, 0.89) times lower for those
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participants reporting cancer, heart attack or angina and other
heart disease, respectively. Those participants who rated their
overall health as being very good (OR=1.53; 95% CI: 1.36, 1.72)
or good (OR=1.52; 95% CI: 1.36, 1.71) were more likely to use
glucosamine as were those participants who rated their overall
quality of life as being excellent (OR=1.28; 95% CI: 1.23, 1.45) or
very good (OR=1.25; 95% CI: 1.10, 1.41).
Participants were more likely to use glucosamine if they were:
former smokers (OR=1.84; 95% CI: 1.74, 1.95) or never smoked
(OR=1.81; 95% CI: 1.70, 1.92), compared to current smokers;
had a household annual income of $20000–$49999 (OR=1.27;
95% CI: 1.23, 1.32) or $50000–$69999 (OR=1.28; 95% CI: 1.22,
1.34), compared to those with an annual income of ,$20000;
were aged 60–69 years (OR=2.34; 95% CI: 2.24, 2.45) or 70–79
years (OR=2.42; 95% CI: 2.29, 2.54), compared to those aged
45–49 years; and were female (OR=1.39; 95% CI: 1.35, 1.43). In
Table 1. Demographic characteristic of people aged 45 years
and older by glucosamine use.
Use of Glucosamine
Demographic Characteristics* Yes No
(n=58,630) (n =208,214)
% (95% C.I.) % (95% C.I.)
Sex Female 60.5 (60.1, 60.9) 51.7 (51.5, 51.9)
Male 39.5 (39.1, 39.9) 48.3 (48.1, 48.5)
Age (years) 45–49 7.6 (7.4, 7.8) 14.6 (14.4, 14.8)
50–59 30.9 (30.5, 31.3) 33.8 (33.6, 34.0)
60–69 33.0 (32.6, 33.4) 26.3 (26.1, 26.5)
70–79 18.6 (18.3, 18.9) 15.0 (14.8, 15.2)
80+ 9.9 (9.7, 10.1) 10.3 (10.2, 10.4)
Place of Major city 44.1 (43.7, 44.5) 45.1 (44.9, 45.3)
Residence Inner regional 36.4 (36.0, 36.8) 35.1 (34.9, 35.3)
Outer regional 17.9 (17.6, 18.2) 17.7 (17.5, 17.9)
Remote/very
remote
1.6 (1.5, 1.7) 2.1 (2.0, 2.2)
Education School Certificate
or less
33.6 (33.2, 34.0) 34.5 (34.3, 34.7)
Higher School
Certificate
9.8 (9.6, 10.0) 10.0 (9.9, 10.1)
Trade/certificate/
diploma
33.2 (32.8, 33.6) 32.1 (31.9, 32.3)
Tertiary 23.4 (23.1, 23.7) 23.4 (23.2, 23.6)
Annual , $20000 24.0 (23.7, 24.3) 25.5 (25.3, 25.7)
Household $20000–$49999 34.3 (33.9, 34.7) 30.8 (30.6, 31.0)
Income $50000–$69999 13.6 (13.3, 13.9) 13.2 (13.1, 13.3)
$ $70000 28.1 (27.7, 28.5) 30.5 (30.3, 30.7)
Marital Status Married/de facto 75.5 (75.2, 75.8) 75.0 (74.8, 75.2)
Widow/divorce/
separ.
19.8 (19.5, 20.1) 19.0 (18.8, 19.2)
Single 4.7 (4.5, 4.9) 6.0 (5.9, 6.1)
Health Private 57.0 (56.6, 57.4) 52.5 (52.3, 52.7)
Insurance DVA or HCC 29.8 (29.4, 30.2) 29.5 (29.3, 29.7)
None 13.2 (12.9, 13.5) 18.0 (17.8, 18.2)
*all characteristics were significantly associated with use of glucosamine
(p,0.0001).
doi:10.1371/journal.pone.0041540.t001
Table 2. Health status characteristics of people aged 45 years
and older by glucosamine use.
Use of Glucosamine
Health Status Characteristics* Yes No
(n=58,630) (n =208,214)
% (95% C.I.) % (95% C.I.)
Smoking Status Current smoker 3.9 (3.7, 4.1) 8.2 (8.1, 8.3)
Former smoker 36.4 (36.0, 36.8) 35.5 (35.3, 35.7)
Never smoked 59.6 (59.2, 60.0) 56.3 (59.4, 59.8)
Alcohol 0–6 drinks
per week
62.1 (61.7, 62.5) 62.4 (62.2, 62.6)
Consumption 7–13 drinks
per week
19.9 (19.6, 20.2) 18.6 (18.4, 18.8)
14–20 drinks
per week
11.3 (11.0, 11.6) 11.0 (10.9, 11.1)
$21 drinks
per week
6.7 (6.5, 6.9) 7.9 (7.8, 8.0)
Overall Health Excellent 14.0 (13.7, 14.3) 15.4 (15.2, 15.6)
Very Good 38.6 (38.2, 39.0) 36.4 (36.2, 36.6)
Good 34.8 (34.4, 35.2) 33.5 (33.3, 33.7)
Fair 11.1 (10.8, 11.4) 12.3 (12.2, 12.4)
Poor 1.5 (1.4, 1.6) 2.4 (2.3, 2.5)
Overall Quality Excellent 23.7 (23.4, 24.0) 23.7 (23.5, 23.9)
Of Life Very Good 38.8 (38.4, 39.2) 36.9 (36.7, 37.1)
Good 28.3 (27.9, 28.7) 28.3 (28.1, 28.5)
Fair 8.0 (7.8, 8.2) 9.2 (9.1, 9.3)
Poor 1.2 (1.1, 1.3) 1.9 (1.8, 2.0)
Osteoarthritis Yes 16.6 (16.3, 16.9) 5.7 (5.6, 5.8)
No 83.4 (83.1, 83.7) 94.3 (94.2, 94.4)
Osteoporosis Yes 7.8 (7.6, 8.0) 5.2 (5.1, 5.3)
No 92.2 (92.0, 92.4) 94.8 (94.7, 94.9)
Asthma Yes 5.3 (5.1, 5.5) 4.6 (4.5, 4.7)
No 94.7 (94.5, 94.9) 95.4 (95.3, 95.5)
Cancer Yes 2.4 (2.3, 2.5) 2.9 (2.8, 3.0)
No 97.6 (97.5, 97.7) 97.1 (97.0, 97.2)
High Blood Yes 26.4 (26.0, 26.8) 23.8 (23.6, 24.0)
Pressure No 73.6 (73.2, 74.0) 76.2 (76.0, 76.4)
High Cholesterol Yes 16.6 (16.3, 16.9) 14.8 (14.6, 15.0)
No 83.4 (83.1, 83.7) 85.2 (85.0, 85.4)
Heart Attack or Yes 2.3 (2.2, 2.4) 2.7 (2.6, 2.8)
Angina No 97.7 (97.6, 97.8) 97.3 (97.2, 97.4)
Other Heart Yes 2.6 (2.5, 2.7) 2.8 (2.7, 2.9)
Disease No 97.4 (97.3, 97.5) 97.2 (97.1, 97.3)
Thyroid Yes 6.0 (5.8, 6.2) 4.7 (4.6, 4.8)
Problems No 94.0 (93.8, 94.2) 95.3 (95.2, 95.4)
Anxiety Yes 4.2 (4.0, 4.4) 4.3 (4.2, 4.4)
No 95.8 (95.6, 96.0) 95.7 (95.6, 95.8)
Depression Yes 6.6 (6.4, 6.8) 6.9 (6.8, 7.0)
No 93.4 (93.2, 93.6) 93.1 (93.0, 93.2)
*all characteristics were significantly associated with use of glucosamine
(p,0.001), with the exception of anxiety (p = 0.3856) and depression
(p = 0.0178).
doi:10.1371/journal.pone.0041540.t002
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comparison to those participants who live in a major city, the odds
of glucosamine use are greater for those living in inner regional
areas (OR=1.05; 95% CI: 1.02, 1.08) and outer regional areas
(OR=1.09; 95% CI: 1.05, 1.13), but lower for those living in
remote or very remote areas (OR=0.83; 95% CI: 0.75, 0.92).
Participants with no health insurance were 0.75 (95% CI: 0.72,
0.78) times less likely use glucosamine compared to participants
with private health insurance. The Hosmer-Lemeshow goodness-
of-fit test statistic for this model is statistically significant (x2 = 34.5;
p,0.0001).
Discussion
Our research findings show that 22% of the study participants,
who are aged 45 years and older, consume glucosamine. This is far
higher than the level of use recorded by a 5-year prospective study
in Canada (4.7% for women; 8.2% for men) [24]. One possible
explanation for this difference is that the Canadian study covered
the period between 1996 and 2001 and glucosamine has become
far more popular since this time given emerging evidence that
suggests potential benefits and the subsequent media coverage
[12]. However, the level of glucosamine use identified from our
study is similar to that of the United States as identified in
a national CAM survey in 2007 [6] as well as findings from three
Australian studies reporting glucosamine use ranging from 15–
33% [9–11] and confirms that glucosamine is one of the most
commonly used CAM in Australia.
Our study findings, that being female, of increased age and
completing advanced education are all associated with glucos-
amine use, are also in line with the results of previous glucosamine
consumption research [24] as well as the identified predictors of
CAM use more broadly [6,38–41]. The association of glucosamine
use with higher annual income and private health insurance
(optional in Australia) is not too surprising given that glucosamine,
like many CAM products, is not subsidised by the Pharmaceutical
Benefits Scheme (a Federal government program providing
subsidised prescription drugs to residents) and attracts an added
10% goods and services tax in Australia.
The association of glucosamine use with osteoarthritis may
reflect the increase in popularity of these products as alternative
treatments for this particular condition [13]. Glucosamine is
largely promoted and recommended for arthritis, so this finding is
not unexpected [12–14]. However, the finding of a negative
association of glucosamine use with cancer, heart disease and
other cardiovascular conditions is revealing. A systematic review of
the prevalence of dietary supplement use in cardiac patients found
that while 36% of patients reported supplement use (across 20
studies), only 4% of patients (across 8 studies) had reported taking
glucosamine/chondroitin [42]. Lower use in cardiac patients may
be related to patients’ concerns and/or professional advice
regarding the potential for drug interactions with prescription
antiplatelets or anticoagulants [43] or simply that glucosamine is
not advocated for the treatment of heart disease. This is an issue
that warrants further investigation.
Our study also reveals that Australians who have better quality
of life/health ratings or a healthy lifestyle (e.g. non-smoking) have
greater odds of glucosamine use. Such findings are interesting in as
much as they may support the idea that glucosamine is used not
only for symptom management but also as a preventive therapy
[24]. This is further supported by the fact that Australian health
professionals support the use of glucosamine for preventative
purposes (20.6% of GPs and 23.4% of community pharmacists
surveyed recommended glucosamine for prevention) [7]. Given
these results it would be useful for future studies to differentiate
between the therapeutic and preventive use of glucosamine and to
explore the reasons for patient’s different use of CAM.
Finally, the study results reveal a major geographical difference
in the consumption of glucosamine with use more likely among
those living in rural areas (though not in very remote areas). This
spatial differentiation in the consumption of supplements has not
been analysed in previous work due a focus upon a much higher
Table 3. Multiple logistic regression model for predicting use
of glucosamine in people aged 45 years and older.
Factor
Odds
Ratio 95% C.I. p-value
Sex Male 1.00 –
Female 1.39 1.35, 1.43 ,0.0001
Age 45–49 1.00 –
50–59 1.68 1.61, 1.75 ,0.0001
60–69 2.34 2.24, 2.45 ,0.0001
70–79 2.42 2.29, 2.54 ,0.0001
80+ 2.03 1.91, 2.15 ,0.0001
Place of Major city 1.00 –
Residence Inner regional 1.05 1.02, 1.08 ,0.0001
Outer regional 1.09 1.05, 1.13 ,0.0001
Remote/very remote 0.83 0.75,0.92 ,0.0001
Annual , $20000 1.00 –
Household $20000–$49999 1.27 1.23, 1.32 ,0.0001
Income $50000–$69999 1.28 1.22, 1.34 ,0.0001
$ $70000 1.21 1.16, 1.27 0.0546
Insurance Private 1.00 –
DVA or HCC 0.86 0.83, 0.89 0.7908
None 0.75 0.72, 0.78 ,0.0001
Smoking Current smoker 1.00 –
Status Former smoker 1.84 1.74, 1.95 ,0.0001
Never smoked 1.81 1.70, 1.92 ,0.0001
Overall Poor 1.00 –
Health Fair 1.36 1.22, 1.52 0.3362
Good 1.52 1.36, 1.71 ,0.0001
Very Good 1.53 1.36, 1.72 ,0.0001




Of Life Fair 1.16 1.02,1.31 0.5594
Good 1.20 1.06, 1.36 0.1894
Very Good 1.25 1.10, 1.41 0.0005
Excellent 1.28 1.23, 1.45 ,0.0001
Osteoarthritis No 1.00 –
Yes 3.31 3.18, 3.45 ,0.0001
Cancer No 1.00 –




Angina Yes 0.79 0.73, 0.86 ,0.0001
Other Heart No 1.00 –
Disease Yes 0.82 0.76, 0.89 ,0.0001
doi:10.1371/journal.pone.0041540.t003
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proportion of urban residents compared to rural residents [24].
The finding of higher glucosamine use in rural regions is in line
with previous studies examining the spatial determinants of CAM
use more broadly [38,44,45]. The discovery of an urban-rural
difference in glucosamine use suggests that further research is
needed to explicate the characteristics and diversity of such use in
different geographical settings.
The study finding of a high prevalence of glucosamine use
among older Australians suggests the need for policy attention
regarding glucosamine consumption and CAM use more broadly.
The association of glucosamine use with osteoarthritis suggests that
consumers may be critically selective in their CAM consumption,
employing glucosamine primarily as indicated rather than
extending use of popular supplements to non-indicated conditions.
The negative association of glucosamine use with cardiovascular
disease may suggest that consumers are taking heed of publicly
available information regarding interactions between glucosamine
and medicines used in the treatment of cardiovascular disease.
Given glucosamine is the most commonly recommended CAM by
GPs and community pharmacists in Australia [7,8], future
research is needed on the role healthcare professionals play in
the decision-making of patients’ use of CAM, as well as the
information sources that patients use to make decisions related to
self-prescription.
The high use of glucosamine in Australia also highlights a need
for more detailed policy attention on CAM. Differences in the
formulation of glucosamine products – either through differing
manufacturing processes or different raw or constituent materials –
is identified as a factor contributing to the heterogeneity in clinical
trial results [23,24]. Moreover, evidence suggests glucosamine
hydrochloride products are associated with more negative results
than glucosamine sulphate products [16,17,46,47]. However,
Australian regulatory and health authorities have not traditionally
made distinctions between specific formulations, and little is
known about public preferences between formulations. As such,
health care policymakers and researchers need to be alert to the
varying quality of supplement products employed by the general
public in order to maximize potential benefit and minimize
possible harm. As such, glucosamine, along with other comple-
mentary medicines, should not be evaluated as a broad category
but in terms of specific commercial formulations.
The interpretation of our findings is limited by the fact that
health and health care use is self-reported by the participants and
as such study results may be open to the effects of recall bias or
self-diagnosis. The interpretation of the study findings is also
limited by the fact that the variable used from the 45 and Up
Study survey was based on those reported as being ‘treated in last
month’ rather than ‘ever been diagnosed’. Further, the 45 and Up
study questionnaire was not developed for the specific purpose of
examining glucosamine use. As our research is a secondary
analysis of the 45 and Up data, we are limited to the questions
devised by the 45 and Up Study investigators and as such, some
potential factors predicting glucosamine use may be missing.
Nevertheless, these limitations are outstripped by the insight
gained through collecting and analysing such a large sample of
adults aged 45 years and older.
Conclusion
Glucosamine has become a popular alternative treatment for
osteoarthritis and this study has estimated that a considerable
proportion of the study participants (aged 45 and over) consume
glucosamine. The high utilisation of glucosamine may have
important clinical ramifications; highlighting the need for primary
care providers to discuss self-prescribed CAM use (including
glucosamine use) with all their patients, not just those that they
suspect of being users. Additionally, given the product variability
and quality issues surrounding glucosamine preparations, the high
utilisation of glucosamine highlights the need for further attention
to these issues to ensure effective application in the treatment or
prevention of osteoarthritis.
Given the concerns raised over potential drug interactions
between glucosamine and common pharmaceuticals such as
warfarin, it is important for the medical profession to be aware
of the use of this dietary supplement among their patients and for
researchers to further investigate the reasons for and details of
glucosamine use.
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